NewsNovo

Rein Therapeutics opens RENEW Phase 2 enrollment for LTI-03 as IPF field reaches three approved drugs

9/6/2026

LTI-03, Rein Therapeutics' (RNTX) inhaled caveolin scaffolding domain peptide for idiopathic pulmonary fibrosis, is now enrolling in the RENEW Phase 2 trial (NCT06968845).

The case for the drug rests on a cell-type targeting profile its developers say the three approved competitors do not match.

What complicates that argument is the presence of Ofev, which cleared more than $4 billion in annual sales as the global market leader, and a cash runway Rein's own filings say may not extend past the first quarter of 2028.

IPF carries a median survival of three to five years from diagnosis, affecting an estimated 40,000 to 110,000 Americans, with more than 250,000 living with some form of pulmonary fibrosis.